News

People with cystic fibrosis (CF) who have mild depression or anxiety report heightened stress, with significantly lower scores on 10 of 12 measures of health-related life quality as compared with the general population of CF patients, new research shows.  According to…

Despite longer hospital stays and higher costs, adults with cystic fibrosis (CF) do not have a greater risk of death from surgery to remove the gallbladder — called a cholecystectomy — compared with people who do not have CF, a study reported. “Importantly, we found that cholecystectomy had very…

Elexacaftor (VX-445), a next-generation CFTR corrector that is part of the triple-combination therapy Trikafta, is also a potentiator, a study reports. Results further showed that in combination with ivacaftor, sold as Kalydeco and also a potentiator, elexacaftor boosts ion flow across CFTR, the…

Use of inhaled hypertonic saline can lessen cystic fibrosis (CF)-related lung damage in young children with the disease, data from a clinical trial indicates. Based on these finding, “we can conclude that hypertonic saline is an effective, safe, and cheap treatment option for preschool children with CF,” said Harm Tiddens,…

Trikafta treatment can reduce the frequency of pulmonary exacerbations — times when lung symptoms get markedly worse — for people with cystic fibrosis (CF). That’s according to an analysis of real-world data shared at this year’s North American Cystic Fibrosis Conference (NACFC), in an oral presentation, “…

Personalized treatment with bacteria-infecting viruses, called bacteriophages, could be used to combat Pseudomonas aeruginosa, the main bacteria involved in lung infections in people with cystic fibrosis (CF), both by killing the bacteria and making them less resistant to antibiotics. Bacteriophage therapy “is safe, decreases P. aeruginosa titers [levels], and…

Treatment with Trikafta may improve nutritional status or lessen anemia among some people with cystic fibrosis (CF) who have received a lung transplant, but more research is needed to understand the potential benefits — and risks — of using the triple-combination medication in this particular patient population. That’s…

Treatment with Trikafta lowered the need for antibiotics and mucus-clearing therapies among children and adolescents with cystic fibrosis being followed at a pediatric CF center in Utah.  Jeffery T. Zobell, a clinical pharmacist at Primary…

Treatment with Trikafta rapidly eases symptoms of chronic nose and sinus inflammation in people with cystic fibrosis (CF), according to a new study — in which researchers noted that 30-60% of CF patients report symptoms of sinus disease. …

Treatment with Trikafta improves lung function in people with cystic fibrosis (CF) who are not eligible for treatment with other CFTR modulators, according to interim data from an observational study. Results were shared at this year’s North American Cystic Fibrosis Conference (NACFC) in the presentation, “…